Abstract
3518 Background: Concurrent CRT is standard treatment for patients with SCCA. We explored CRT compliance in ACT II, which compared 5FU/CisP with 5FU/MMC (wks 1 & 5) of a uniform RT dose (50.4Gy, 28 daily fractions (F) of 1.8Gy). Methods: We investigated the association between poor compliance and baseline factors (age, sex, site, T & N stage), type of CT (MMC/CisP) with progression free survival (PFS). Compliance was categorized as follows: RT, 5 groups: A = per protocol (50.4Gy in 28F in 38-42 days), B = ≤ 40Gy, C = 40-48.6Gy in 23-27F, D = 50.4Gy in > 42 days, E > 52.2Gy. CT, 2 groups: 1 = wks1 & 5 & 2 = wk1 only. Results: 933 and 862 of 940 pts were evaluable for RT & CT compliance respectively. Median follow-up was 5.1 yrs. Baseline characteristics of evaluable patients were similar to all 940 ACT II patients. Canal tumors, CisP, GFR<60 & WBC < 11 were borderline significant predictors of poor wk5 CT compliance (p 0.09, 0.07, 0.06 & 0.08 respectively). Poor CT compliance at wk5 impacted significantly ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
